文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19靶向CAR-T细胞疗法治疗富含T细胞/组织细胞的大B细胞淋巴瘤

CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

该研究通过国际血液与骨髓移植研究中心注册库,纳入2018至2022年间接受商业化CD19-CAR-T治疗的58例复发/难治性富含T细胞/组织细胞的大B细胞淋巴瘤成人患者。中位随访23个月时,2年总生存率为42%(95%CI 27-57),无进展生存率为29%(95%CI 17-43)。尽管2年累积进展发生率达69%,结果提示部分患者可能获得持久缓解。

要点

  • 58例复发/难治性THRLBCL患者接受CD19-CAR-T,2年OS为42%,PFS为29%。
  • 2年累积复发/进展发生率为69%,非复发死亡率为2%。
  • ≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征分别发生7%和15%。

核心结论

  • 在这项针对复发/难治性THRLBCL的最大规模CD19-CAR-T分析中,约30%的患者在CAR-T治疗后2年存活且无进展。
  • 尽管2年进展发生率高达69%,结果提示部分复发/难治性THRLBCL患者可能通过CAR-T获得持久缓解。

研究设计与样本

  • 通过国际血液与骨髓移植研究中心注册库开展的回顾性分析,纳入2018至2022年间接受商业化CD19-CAR-T治疗的58例复发/难治性THRLBCL成人患者。

主要发现

  • 67%的患者为早期复发(45%原发难治),既往治疗中位数为3线(范围1-7),69%接受阿基仑赛治疗。
  • CAR-T治疗后中位随访23个月,2年总生存率为42%(95%CI 27-57),无进展生存率为29%(95%CI 17-43)。
  • 单因素分析中,CAR-T治疗前体能状态差与更高死亡率相关(HR 2.35;95%CI 1.02-5.5)。
  • 2年累积复发/进展发生率为69%,非复发死亡率为2%。
  • ≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征分别发生于7%和15%的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the Center for International Blood and Marrow Transplant Research registry. A total of 58 adult patients with R/R THRLBCL who received commercial CD19-CART therapy between 2018 and 2022 were identified. Most patients (67%) had early relapse of disease (45% primary refractory) with a median of 3 (range, 1-7) prior therapies and were treated with axicabtagene ciloleucel (69%). At median follow-up of 23 months after CART therapy, 2-year overall and progression-free survival were 42% (95% confidence interval [CI], 27-57) and 29% (95% CI, 17-43), respectively. In univariable analysis, poor performance status before CART therapy was associated with higher mortality (hazard ratio, 2.35; 95%CI, 1.02-5.5). The 2-year cumulative incidences of relapse/progression and nonrelapse mortality were 69% and 2%, respectively. Grade ≥3 cytokine release syndrome and immune effector cell-associated neurologic syndrome occurred in 7% and 15% of patients, respectively. In this largest analysis of CD19-CART therapy for R/R THRLBCL, ∼30% of patients were alive and progression free 2 years after CART therapy. Despite a high incidence of progression (69% at 2 years), these results suggest a subset of patients with R/R THRLBCL may have durable responses with CARTs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pophali PA, Fein JA, Ahn KW, et al. CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma. Blood Adv. 2024. PMID: 38985302. doi:10.1182/bloodadvances.2024013863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。